You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AFM based nanoscale IR Spectroscopy (AFM-IR) as a characterization platform for P

    SBC: Anasys Instruments Corp.            Topic: 300

    DESCRIPTION provided by applicant Anasys Instruments and Prof Lynne Taylor of Purdue propose to develop nanoscale chemical characterization capabilities for drug formulation research This project will build on successful Phase I research demonstrating feasibility of atomic force microscope based infrared spectroscopy AFM IR in pharmaceutical applications This Phase II research will advance ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Real-time PCR Diagnostic Kit for Giardia and Cryptosporidium

    SBC: PHRIXUS PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This two-year proposal seeks small business support for IDX Labs LLC to continue collaborating with Dr. Houpt at the University of Virginia to bring sensitive real-time PCR (qPCR) tests for Giardia and Cryptosporidium t o U.S. labs. According to the CDC, these parasites infect up to 2 million Americans annually, and we have developed robust sensitive qPCR tests ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced Technology and Tools for DBS Programming for Speech Functionality

    SBC: Speech Technology and Applied Research Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Speech is a complex motor behavior often disrupted by neurological dysfunction. Parkinson's disease (PD) is one of the main disorders disrupting speech. Recently, deep brain stimulation (DBS) has proven to be effective for motor problems in patients with PD and other movement disorders. However, the effects of DBS on speech have not been consistently positive ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: PROTEIN METRICS INC            Topic: 400

    Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical Development of 2nd Generation HIV Maturation Inhibitors

    SBC: DFH Pharma, Inc            Topic: NIAID

    Project Summary: While currently available antiretroviral therapies are highly effective they are not curative. Patients are required to remain on life-long therapy which is associated with a variety adverse effects. Over time, viral-mediated drug resistance is likely to pose an increasingly serious problem for individuals on therapy. The development of novel classes of inhibitors that block viral ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Alkoxylamine nucleosides for sequencing by synthesis

    SBC: INTELLIGENT BIO-SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Sequencing during synthesis (SdS) is an architecture for massively parallel DNA sequencing that has the strong potential of lowering the cost of sequencing enough to allow individuals access to their own genetic heritag e as a way of personalizing their medical care. Thus far, however, higher-throughput next-generation sequencing systems are relatively expensiv ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Advanced Detection Technologies for Biochips

    SBC: INDEVR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of the proposed work is the development of innovative detection technologies for biochips (a.k.a. DNA microarrays). It is envisioned that the proposed technologies will enable the application of biochips to biodefense, particularly when a rapid and reliable diagnostic screen is required in the field. The Specific Aims of the proposed wo ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Anti-Aging Mitochondrial Protein Therapy for Alzheimer?s Disease and Sarcopenia

    SBC: Gencia Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The decline of motor and cognitive function in aging finds an extreme manifestation in the form of sarcopenia and senile dementia, most commonly of the Alzheimer's type. Both are associated with mitochondrial dysfunction. In sarcopenia there is accumulation of mitochondrial DNA (mtDNA) deletions and loss of oxidative capacity in the muscle. In the Alzheimer's b ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government